Staying on Track: How to Maximize Your HIV Treatment During and After Pregnancy
"A Deep Dive into Adherence Strategies for Women in Malawi's Option B+ Program"
For women living with HIV, consistent adherence to antiretroviral therapy (ART) is essential, especially during and after pregnancy. This adherence not only protects the mother’s health but also significantly reduces the risk of transmitting the virus to her child. However, maintaining this adherence can be challenging, influenced by various personal and systemic factors.
A groundbreaking initiative called Option B+ was introduced in Malawi in 2011, offering lifelong ART to pregnant and breastfeeding women with HIV, regardless of their clinical stage. This program aimed to simplify treatment access and improve outcomes, yet questions remained about how well women adhered to their medication regimens, particularly in the long term. Understanding adherence patterns is crucial for optimizing the effectiveness of such programs and ensuring the well-being of both mother and child.
A recent study delved into the adherence rates among women enrolled in Malawi's Option B+ program. By analyzing pharmacy claim data from 13 large health facilities, researchers uncovered important trends and risk factors affecting adherence. This article breaks down the study’s findings, offering actionable insights for women, healthcare providers, and policymakers alike to improve HIV treatment outcomes during and after pregnancy.
HIV Treatment Adherence: The Global Challenge
Measuring HIV treatment adherence in clinical settings is feasible, but the growing number of multi-site Electronic Health Records (EHR) systems presents challenges for adequate informatics methods to handle data effectively. Adherence measurement includes patient self-report, tablet counts, pharmacy records, electronic monitoring, or composite methods, each with varying accuracy for detecting non-suppressed viral load. UNAIDS data from 172 countries reporting for 2025 will be made available on aidsinfo.unaids.org as of July 27, 2026. Determinants of adherence to daily PrEP are measured as intracellular drug concentrations, with statistical analyses performed in STATA V.15.1.
Adherence Counselling and Medication Management
The aim of a drug adherence counselling programme is to enhance adherence to HAART for maximising treatment outcome, achieving the target of improving individual health clinically and lowering HIV infectivity on a public health level. Taking medication as prescribed is often called 'adherence', which includes following instructions about food and checking for drug-drug interactions. Treatment adherence includes starting HIV treatment, keeping all medical appointments, and taking HIV medications every day and exactly as prescribed. Considerations drawn from HIV treatment adherence research inform approaches to biomedical HIV prevention methods.
Evolution of HIV Treatment and Adherence
HIV treatment involves antiretroviral drugs that suppress the virus, boosting immune function and improving patients' quality of life, with staying adherent to ART being one of the most important aspects of treating HIV. When a person has HIV and is in treatment, some symptoms they experience could be from the medicine they're taking, which can help them stay healthy with the virus and prevent transmission. Treatment adherence is crucial for better health outcomes, emotional well-being, and a sense of achievement, with accessibility, education, and social support significantly influencing consistency. The next phase of competition in the HIV market will be defined not only by achieving viral suppression, but by improving treatment adherence, reducing medication burden, and delivering more convenient treatment options, with long-acting therapies at the forefront.
Key Findings: Adherence Patterns in Malawi
The study, which examined data from September 2011 to October 2013, defined adherence as the percentage of days covered by pharmacy claims, with 90% or greater adherence considered adequate. The findings revealed that while a significant proportion of women showed good adherence, challenges persisted, especially postpartum.
- During Pregnancy: 73% of women demonstrated adequate adherence.
- First 3 Months Postpartum: Adherence dipped to 66%.
- Months 4-21 Postpartum: Adherence rebounded to about 75%.
- Consistent Adherence: Only 30% maintained adequate adherence at every visit during the first two years of ART.
Education, Life Stress, and Treatment Adherence
Social policy makers frequently leverage formal schooling as a tool for curbing the HIV epidemic in sub-Saharan Africa, yet evidence about the association between formal education and chronic HIV care and treatment in the era of 'Treatment as Prevention' remains limited. Successful HIV treatment is contingent on sustained high levels of treatment adherence, with several barriers to optimal adherence documented on a public health scale. Treatment adherence is extremely important for virological suppression and a good clinical outcome in HIV, with people experiencing better clinical courses when adherence is maintained. A longitudinal investigation has examined the impact of life stress on HIV treatment adherence, alongside self-report measures of antiretroviral therapy adherence reviewed with recommendations for HIV research and clinical management.
Barriers and Limitations in Achieving Adherence
Treatment adherence includes starting HIV treatment, keeping all medical appointments, and taking HIV medicines exactly as prescribed, which is key to staying healthy for people with HIV. Research suggests the interconnection of HIV treatment adherence barriers at various system levels, indicating that future studies should explore these interactions and investigate possible synergistic effects on non-adherent behavior. Treatment adherence is critical for HIV positive individuals, but many find it challenging to maintain, with recommended treatment guidelines including adherence obstacles and benefits. A study was limited by a small sample size in groups with lower adherence, which may have reduced the statistical power to detect significant differences, and all measures were self-reported, introducing social desirability bias and recall bias.
Psychopathology and Mental Health in Treatment Adherence
A case-control survey was designed to compare the prevalence of mental illness (excluding substance misuse) among patients followed up in HIV consultations who are receiving antiretroviral therapy (ART) from Hospital Pharmacy. HIV is treated with antiretroviral therapy consisting of one or more medicines, which does not cure HIV but reduces its replication in the blood, thereby reducing the viral load to an undetectable level. ART enables people living with HIV to lead healthy, productive lives, though differences in psychopathology exist between adherent and non-adherent patients. Understanding these mental health factors is essential for developing targeted interventions to improve treatment outcomes.
Moving Forward: Improving Adherence and Outcomes
The study underscores the need for targeted interventions to support women in maintaining consistent adherence to ART, particularly during the critical postpartum period. Strategies such as adherence counseling, text message reminders, and community support groups can play a vital role in improving outcomes. Additionally, healthcare providers should be aware of the risk factors for non-adherence and tailor their support accordingly to ensure the long-term success of HIV treatment and prevention efforts.
Expert and Patient Perspectives on ART Adherence
Exploring expert and patient opinions and recommendations regarding anti-retroviral treatment compliance reveals that the importance of dedicated adherence to ART in HIV management is well documented. Research shows the total number of articles in HIV treatment adherence among adolescents and young adults across all publications each year, indicating growing scholarly attention to this population. Chronic HIV infection occurs when initial symptoms have cleared, but the infection persists at lower levels in the blood, with the virus remaining contagious even if a person is asymptomatic. Integrating expert knowledge with patient experiences provides comprehensive insights into improving ART adherence strategies.
Innovations and Peer Support in HIV Treatment
The HIV drugs market is at a critical juncture, with scientific advancements and global healthcare initiatives shaping its trajectory, as the industry continues to evolve toward making HIV treatment more effective, accessible, and sustainable worldwide. Three areas where HIV treatment adherence literature can inform research on biomedical prevention strategies include specialized methods for assessing medication adherence, research findings emphasizing social context as an adherence determinant, and considerations from prevention research. The Rise project led to increased ART adherence, lower HIV stigma, and reduced medical mistrust (such as less belief that ART is poison) through peer counseling interventions. These innovations represent promising frontiers for improving treatment outcomes and patient engagement.
Stigma, Socioeconomic Barriers, and Healthcare Access
Despite increased access to antiretroviral therapy (ART), adherence and retention in care remain problematic in many parts of West Africa, including the Republic of Guinea, where stigma, socioeconomic challenges, and healthcare access are key factors influencing treatment outcomes. In describing their role in HIV care and treatment, many health workers perceived themselves as 'healers' and providers of help with the ability and mandate to treat opportunistic infections, provide drugs, manage adverse reactions, and address adherence challenges. These systemic barriers create complex environments where maintaining consistent treatment becomes difficult for patients. Understanding the interplay between stigma, economic factors, and healthcare system capacity is essential for developing effective interventions.
Medicare, Gender, and Economic Incentives
Approximately one-quarter of people with HIV (PWH) in the U.S. receive coverage through the Medicare program; however, no prior real-world study has examined antiretroviral therapy (ART) gaps and adherence and associated factors in this population. Few previous studies have assessed viral suppression, a biomarker of adherence and the ultimate goal of HIV 'treatment as prevention' efforts, with questions remaining around pathways of impact, best practices for real-world implementation, and durability of effects. Both gender and HIV stigma are known to contribute to poor retention to antiretroviral therapy (ART), but little is known how they interact in decisions about adherence or default by people living with HIV (PLWH). Conditional economic incentives represent a promising approach to improve adherence, though research is needed to understand their effectiveness in real-world settings.